Eli Lilly merges GLP-1 cash with AI research
The long thesis presented for Eli Lilly frames the company as a hybrid pharmaceutical and AI innovator funding proprietary model training via lucrative GLP-1 drug revenues.
Sign in to read the full idea
The argument, what validates it, the risks discussed and hearing it from the source are for signed-in members. Free accounts read 3 ideas in full a day. No card required.